Backed By Peyton Manning, Eli Manning, BBQGuys Lands SPAC Deal: What Investors Should Know
The largest e-commerce platform for higher-end BBQ grills and outdoor living products is going public with a SPAC deal announced Tuesday.
Earnings Pace Picks Up Later Today With Chipotle, Netflix Expected To Report
On the day Amazon (NASDAQ: AMZN) founder Jeff Bezos launches himself into space, most investors would probably be happy just to see the major indices pick themselves off the carpet after yesterday’s meltdown.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
SEC Pushes Harder On SPACs With PSTH Pressure, SRAC Fine
The SEC has been circling around SPACs in 2021. The company’s pressure on how warrants were recognized by companies led to a backlog of deal votes and company’s set to publicly list. Two SPAC deals have been targeted by the SEC in a move that could change the SPAC market.
Duolingo Targeting $3.4B IPO Stemming From Online Learning Boom: Reuters
Language-learning app maker Duolingo Inc (NASDAQ:DUOL) is aiming for a $3.41 billion U.S. initial public offering to tap the pandemic-driven…
Nervous System Firm Eliem Therapeutics Files For $80M IPO
Eliem Therapeutics (NASDAQ: ELYM), a Phase 2a biotech developing therapies for neuronal excitability disorders, filed an IPO prospectus with the SEC to raise up to $80 million.
Its two lead candidates are ETX-810 and ETX-155.
Skin-Disease Focused Biotech Castle Creek Files $100M IPO
Ahead of Phase 3 data readout in the second half of next year, Castle Creek Biosciences Inc (NASDAQ: CCBS) seeks to make NASDAQ debut under the symbol CCBS.
FDA-Approved Weight Loss Drug Plenity’s Parent Announces SPAC Deal: What Investors Should Know
A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.
Adagio Files $100M IPO To Take Its COVID-19 Antibody Through Commercialization In 2022
Adagio Therapeutics has filed an initial public offering to raise money to bring its COVID-19 antibody to market.
The $100 million IPO will support Phase 2/3 trials that CEO Tillman Gerngross’ Adagio is running to position ADG20 to treat and prevent COVID-19.